Seroflo Inhaler: Advanced Dual-Therapy Asthma and COPD Control
| Product dosage: 250mcg | |||
|---|---|---|---|
| Package (num) | Per inhaler | Price | Buy |
| 1 | $110.34 | $110.34 (0%) | 🛒 Add to cart |
| 2 | $94.80 | $220.69 $189.59 (14%) | 🛒 Add to cart |
| 3 | $89.28 | $331.03 $267.83 (19%) | 🛒 Add to cart |
| 4 | $86.52 | $441.37 $346.08 (22%) | 🛒 Add to cart |
| 5 | $85.06 | $551.72 $425.32 (23%) | 🛒 Add to cart |
| 6 | $83.93 | $662.06 $503.57 (24%) | 🛒 Add to cart |
| 7 | $83.26 | $772.40 $582.81 (25%) | 🛒 Add to cart |
| 8 | $82.63
Best per inhaler | $882.75 $661.06 (25%) | 🛒 Add to cart |
Synonyms | |||
Similar products
Seroflo represents a significant advancement in respiratory medicine, combining two powerful therapeutic agents into a single, convenient inhaler. This fixed-dose combination inhaler is specifically engineered for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD) in patients requiring both corticosteroid and long-acting bronchodilator therapy. By delivering synchronized medication, Seroflo works to reduce airway inflammation and prevent bronchoconstriction simultaneously, offering superior symptom control compared to monotherapy approaches. Its carefully calibrated formulation makes it a cornerstone treatment for moderate to severe respiratory conditions, providing patients with improved lung function and enhanced quality of life.
Features
- Contains fluticasone propionate (corticosteroid) and salmeterol xinafoate (long-acting beta2-agonist) in precise therapeutic ratios
- Available in multiple strength combinations to accommodate varying patient needs and severity levels
- Utilizes hydrofluoroalkane (HFA) propellant for consistent drug delivery
- Features a dose counter to track remaining medication and ensure treatment adherence
- Engineered with an ergonomic mouthpiece for optimal inhalation technique
- Provides micronized drug particles for deep lung deposition and maximum efficacy
Benefits
- Delivers comprehensive asthma and COPD management through dual-mechanism action
- Significantly reduces frequency and severity of respiratory exacerbations
- Improves lung function measurements (FEV1) within weeks of consistent use
- Minimizes reliance on rescue inhalers through proactive symptom prevention
- Enhances overall quality of life by enabling normal daily activities and sleep
- Simplifies treatment regimens with twice-daily dosing convenience
Common use
Seroflo is primarily prescribed for the maintenance treatment of asthma in patients aged 12 years and older who require both inhaled corticosteroid and long-acting beta2-agonist therapy. It is also indicated for symptomatic treatment of patients with COPD (including chronic bronchitis and emphysema) with a history of repeated exacerbations. Healthcare providers typically recommend Seroflo when symptoms are not adequately controlled with inhaled corticosteroids alone or when disease severity warrants combination therapy from treatment initiation. The medication is not intended for relief of acute bronchospasm but rather for long-term management of chronic respiratory conditions.
Dosage and direction
The appropriate dosage of Seroflo must be individualized based on disease severity and previous therapy. For asthma management in patients 12 years and older, the recommended starting dose is typically one inhalation of Seroflo 100/50 or Seroflo 250/50 twice daily (approximately 12 hours apart). For COPD management, the usual dosage is one inhalation of Seroflo 250/50 twice daily. Patients should be instructed to shake the inhaler well before each use and to exhale fully away from the mouthpiece before placing it in the mouth and inhaling deeply and steadily. After inhalation, patients should hold their breath for about 10 seconds or as long as comfortable before exhaling slowly. The mouth should be rinsed with water without swallowing after each dose to minimize the risk of oral candidiasis.
Precautions
Patients using Seroflo should be monitored regularly for any signs of systemic corticosteroid effects, particularly with higher doses or prolonged use. Caution is advised in patients with tuberculosis, fungal, bacterial, viral, or parasitic infections, or ocular herpes simplex. Seroflo may cause paradoxical bronchospasm in some patients, requiring immediate discontinuation and alternative therapy. Patients should not discontinue Seroflo abruptly, as this may result in clinical deterioration. Regular assessment of height in pediatric patients is recommended due to potential growth suppression. Ophthalmologic examinations are advised for patients at risk for glaucoma or cataracts. Patients should be instructed to seek medical attention if their asthma or COPD symptoms worsen despite using Seroflo.
Contraindications
Seroflo is contraindicated in patients with known hypersensitivity to fluticasone propionate, salmeterol xinafoate, or any component of the formulation. It should not be used as primary treatment for status asthmaticus or other acute episodes of asthma or COPD where intensive measures are required. The medication is contraindicated for the relief of acute symptoms, for which a fast-acting inhaled bronchodilator is required. Seroflo should not be used in combination with other long-acting beta2-agonists due to the increased risk of adverse cardiovascular effects.
Possible side effects
Common side effects may include headache, throat irritation, hoarseness, voice changes, and oral candidiasis (thrush). Upper respiratory tract infections, sinusitis, and pharyngitis have been frequently reported. Less common but potentially serious side effects include pneumonia in COPD patients, cardiovascular effects (tachycardia, palpitations, chest pain), systemic corticosteroid effects (adrenal suppression, reduction in bone mineral density, growth effects in children, cataracts, glaucoma), paradoxical bronchospasm, and immediate hypersensitivity reactions. Patients should report any unusual symptoms, especially increased wheezing immediately after inhalation, chest pain, heart palpitations, nervousness, rash, hives, or swelling of the face, mouth, and tongue.
Drug interaction
Concomitant use with strong cytochrome P450 3A4 inhibitors (such as ketoconazole, ritonavir, clarithromycin) may increase fluticasone systemic exposure and increase the risk of systemic corticosteroid effects. Beta-blockers may antagonize the effects of salmeterol and produce severe bronchospasm in asthma patients. Diuretics may potentiate hypokalemia or ECG changes. Use with other sympathomimetic agents may potentiate sympathetic effects. Monoamine oxidase inhibitors and tricyclic antidepressants may potentiate the cardiovascular effects of salmeterol. Patients should inform their healthcare provider about all medications, including prescription, over-the-counter, and herbal products.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is almost time for the next scheduled dose. In that case, the missed dose should be skipped and the regular dosing schedule resumed. Patients should not double the dose to make up for a missed one. Consistent use is important for optimal control of respiratory symptoms, so patients should try to maintain a regular dosing schedule. If multiple doses are missed, symptoms may worsen, and medical advice should be sought.
Overdose
Overdose may produce symptoms consistent with beta2-agonist overdose, including tachycardia, arrhythmias, tremor, headache, muscle cramps, dry mouth, palpitations, nausea, dizziness, fatigue, malaise, insomnia, hyperglycemia, hypokalemia, and seizures. Fluticasone propionate overdose is unlikely to produce acute problems, but chronic overdose may lead to systemic corticosteroid effects. Treatment should be supportive and symptomatic. Cardiac monitoring is recommended in cases of significant overdose. Dialysis is not appropriate treatment for Seroflo overdose. Medical attention should be sought immediately if overdose is suspected.
Storage
Store at room temperature between 15°C and 30°C (59°F and 86°F). Do not freeze. Keep the canister away from direct sunlight and heat sources. The contents are under pressure—do not puncture or incinerate, even when apparently empty. Store with the mouthpiece down. Keep out of reach of children. The inhaler should be discarded 30 days after removal from the foil pouch or when the dose counter reads “0,” whichever comes first. Do not attempt to take the inhaler apart.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Individual patient needs may vary, and only a qualified healthcare professional can determine appropriate treatment. Patients should not make changes to their medication regimen without consulting their physician. The complete prescribing information should be consulted before initiating therapy. In case of medical emergency, contact local emergency services immediately.
Reviews
Clinical studies demonstrate that Seroflo significantly improves lung function and quality of life compared to monotherapy components alone. In a 12-month study of asthma patients, those using Seroflo experienced 25% fewer severe exacerbations and demonstrated improved morning peak expiratory flow rates. COPD patients showed a 30% reduction in moderate and severe exacerbations compared to placebo. Pulmonary specialists report excellent patient compliance due to the convenience of combination therapy and reduced dosing frequency. Many patients describe improved ability to participate in physical activities and reduced nighttime symptoms. Some users note the importance of proper inhalation technique and regular rinsing to minimize local side effects.